AU773663B2 - Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof - Google Patents

Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof Download PDF

Info

Publication number
AU773663B2
AU773663B2 AU84635/01A AU8463501A AU773663B2 AU 773663 B2 AU773663 B2 AU 773663B2 AU 84635/01 A AU84635/01 A AU 84635/01A AU 8463501 A AU8463501 A AU 8463501A AU 773663 B2 AU773663 B2 AU 773663B2
Authority
AU
Australia
Prior art keywords
iduronidase
mutant
fragment
recombinant
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU84635/01A
Other languages
English (en)
Other versions
AU8463501A (en
Inventor
Wia-Pan Chan
Lin Chen
Paul A. Fitzpatrick
John Henstrand
Emil D. Kakkis
Minmin Qin
Christopher M. Starr
Becky Tanamachi
Dan J. Wendt
Gary N. Zecherle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Original Assignee
Biomarin Pharmaceutical Inc
Harbor UCLA Research and Education Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc, Harbor UCLA Research and Education Institute filed Critical Biomarin Pharmaceutical Inc
Publication of AU8463501A publication Critical patent/AU8463501A/en
Assigned to BIOMARIN PHARMACEUTICAL INC., HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE reassignment BIOMARIN PHARMACEUTICAL INC. Amend patent request/document other than specification (104) Assignors: BIOMARIN PHARMACEUTICAL INC., HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE
Application granted granted Critical
Publication of AU773663B2 publication Critical patent/AU773663B2/en
Assigned to BIOMARIN PHARMACEUTICAL INC., LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOUR-UCLA MEDICAL CENTER reassignment BIOMARIN PHARMACEUTICAL INC. Request to Amend Deed and Register Assignors: BIOMARIN PHARMACEUTICAL INC., HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01075—Glucan endo-1,6-beta-glucosidase (3.2.1.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU84635/01A 1999-11-12 2000-11-09 Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof Expired AU773663B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/439923 1999-11-12
US09/439,923 US6426208B1 (en) 1999-11-12 1999-11-12 Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
PCT/US2000/031293 WO2002004616A1 (en) 1999-11-12 2000-11-09 RECOMBINANT α-L-IDURONIDASE, METHODS FOR PRODUCING AND PURIFYING THE SAME AND METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004208651A Division AU2004208651A1 (en) 1999-11-12 2004-09-03 Recombinant Alpha -L- Iduronidase, Methods for Producing and Purifying the Same and Methods for Treating Diseases Caused by Deficiencies Thereof

Publications (2)

Publication Number Publication Date
AU8463501A AU8463501A (en) 2002-01-21
AU773663B2 true AU773663B2 (en) 2004-06-03

Family

ID=23746702

Family Applications (2)

Application Number Title Priority Date Filing Date
AU84635/01A Expired AU773663B2 (en) 1999-11-12 2000-11-09 Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
AU2004208651A Abandoned AU2004208651A1 (en) 1999-11-12 2004-09-03 Recombinant Alpha -L- Iduronidase, Methods for Producing and Purifying the Same and Methods for Treating Diseases Caused by Deficiencies Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2004208651A Abandoned AU2004208651A1 (en) 1999-11-12 2004-09-03 Recombinant Alpha -L- Iduronidase, Methods for Producing and Purifying the Same and Methods for Treating Diseases Caused by Deficiencies Thereof

Country Status (14)

Country Link
US (3) US6426208B1 (OSRAM)
EP (2) EP1332206B1 (OSRAM)
JP (3) JP2004502456A (OSRAM)
CN (2) CN1420924B (OSRAM)
AT (2) ATE342964T1 (OSRAM)
AU (2) AU773663B2 (OSRAM)
BR (1) BRPI0015533B8 (OSRAM)
CA (1) CA2391098C (OSRAM)
DE (2) DE60031456T2 (OSRAM)
ES (2) ES2324727T3 (OSRAM)
IL (3) IL149568A0 (OSRAM)
MX (1) MXPA02004742A (OSRAM)
WO (1) WO2002004616A1 (OSRAM)
ZA (1) ZA200203619B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569661B1 (en) * 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
EP1368039A4 (en) * 2001-02-20 2006-03-29 Uab Research Foundation AMINOGLYCOSIDE TREATMENT FOR LYSOSOMAL STORAGE DISEASES
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1668110A2 (en) * 2003-08-21 2006-06-14 Q Therapeutics, Inc. Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US8105788B2 (en) * 2005-12-08 2012-01-31 The University Of British Columbia Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith
WO2008116171A1 (en) * 2007-03-21 2008-09-25 Raptor Pharmaceutical Inc. Cyclic receptor-associated protein (rap) peptides
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
ES2387251T3 (es) * 2008-02-21 2012-09-19 Fiat Group Automobiles S.P.A. Conjunto de soporte de vidrio para una puerta de vehículo a motor con un borde superior sin armazón
ES2629853T3 (es) 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
DE102011102170B4 (de) 2011-05-20 2024-06-06 Vitesco Technologies GmbH Einspritzvorrichtung zur Einspritzung eines Fluids
SMT202000445T1 (it) 2012-06-19 2020-09-10 Univ Florida Composizioni e metodi per trattare patologie
ES2994608T3 (en) 2012-08-10 2025-01-27 Osio Corp D/B/A Yolia Health Contact lens use in the treatment of an ophthalmologic condition
JP6591956B2 (ja) 2013-03-15 2019-10-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｍｐｓ１を治療するための組成物および方法
AU2017215211C1 (en) 2016-02-03 2023-11-16 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
MA47436A (fr) * 2017-01-31 2019-12-11 Regenxbio Inc Traitement de la mucopolysaccharidose i avec une alpha-l-iduronidase glycosylée entièrement humaine (idua)
EP3676385A1 (en) 2017-07-06 2020-07-08 The Trustees of The University of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
JP7449223B2 (ja) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を治療するための遺伝子療法
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
US20220023434A1 (en) 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
CN110577559B (zh) * 2019-08-19 2023-02-17 江西科技师范大学 α-L-艾杜糖醛酸酶测定用荧光糖苷酶底物的合成方法
JP7791517B2 (ja) * 2021-01-04 2025-12-24 国立大学法人徳島大学 ライソゾームを標的とした新規ｄｄｓの開発
WO2022145449A1 (ja) * 2021-01-04 2022-07-07 国立大学法人徳島大学 ライソゾームを標的とした新規ｄｄｓの開発
CN115109790A (zh) * 2021-03-23 2022-09-27 北京据德医药科技有限公司 一种重组a-L-艾杜糖醛酸普酶及其制备方法
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用
CN115161284B (zh) * 2022-07-04 2024-07-09 无锡多宁生物科技有限公司 一种lmh悬浮细胞复苏培养方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (OSRAM) 1961-07-20
GB1029548A (en) 1963-07-17 1966-05-11 Amagasaki Iron & Steel Mfg Co Corrugated roofing sheet
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3891757A (en) 1971-11-11 1975-06-24 Alza Corp Anaesthetic topical and percutaneous administration with selected promoters
US5270051A (en) 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
WO1993010244A1 (en) 1991-11-14 1993-05-27 Women's And Children's Hospital Synthetic alpha-l-iduronidase and genetic sequences encoding same
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
US5278051A (en) * 1991-12-12 1994-01-11 New York University Construction of geometrical objects from polynucleotides
AU7071196A (en) 1995-09-14 1997-04-01 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
WO1999058691A2 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAKKIS ET AL (1996) BIOCHEM AND MOLECULER MED. VOL.58:156-7 *
UNGER ET AL (1994) BIOCHEM J. VOL. 304:43-49 *

Also Published As

Publication number Publication date
EP1792983B1 (en) 2009-04-29
AU2004208651A1 (en) 2004-09-30
ES2273748T3 (es) 2007-05-16
AU8463501A (en) 2002-01-21
IL149568A (en) 2010-04-29
US20030013179A1 (en) 2003-01-16
ZA200203619B (en) 2003-07-30
ATE430193T1 (de) 2009-05-15
US7041487B2 (en) 2006-05-09
BRPI0015533B1 (pt) 2020-12-08
HK1057059A1 (en) 2004-03-12
US20060286087A1 (en) 2006-12-21
JP3857705B2 (ja) 2006-12-13
CA2391098A1 (en) 2002-01-17
ATE342964T1 (de) 2006-11-15
EP1332206B1 (en) 2006-10-18
CN1420924B (zh) 2010-05-05
ES2324727T3 (es) 2009-08-13
JP2004502456A (ja) 2004-01-29
WO2002004616A1 (en) 2002-01-17
BRPI0015533B8 (pt) 2021-05-25
CA2391098C (en) 2007-10-23
US6426208B1 (en) 2002-07-30
JP2005046154A (ja) 2005-02-24
CN1420924A (zh) 2003-05-28
MXPA02004742A (es) 2005-09-08
IL192078A0 (en) 2008-12-29
EP1792983A1 (en) 2007-06-06
JP2006312648A (ja) 2006-11-16
DE60031456T2 (de) 2007-08-23
DE60042137D1 (de) 2009-06-10
BR0015533A (pt) 2002-06-25
DE60031456D1 (de) 2006-11-30
HK1104836A1 (en) 2008-01-25
EP1332206A1 (en) 2003-08-06
IL149568A0 (en) 2002-11-10
CN101407796A (zh) 2009-04-15
IL192078A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
CA2391098C (en) Recombinant .alpha.-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US20020127652A1 (en) Follicle stimulating hormones
CA2825163C (en) Compositions for regulating iron homeostasis and methods of using same
US20030036181A1 (en) Peptide extended glycosylated polypeptides
KR20150038636A (ko) 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도
CA2328518A1 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
BR9712767B1 (pt) sequência de ácidos nucléicos codificando um polipeptìdio de fusão bem como vetor compreendendo a dita sequência.
MXPA00011137A (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
CN104862336B (zh) 一种表达乙肝病毒受体——人ntcp的小鼠模型的构建方法
RU2766680C1 (ru) Новые варианты гиалуронидазы и содержащая их фармацевтическая композиция
US20060040348A1 (en) Methods for producing and purifying recombinant alpha-L-iduronidase
CN107287240B (zh) 一种用于治疗2型全色盲病人的重组腺相关病毒基因治疗载体及药物
WO2026052952A1 (en) Compositions and methods of therapy
CN102051378A (zh) 以病毒mRNA核转运为靶点的抗HIV-1药物筛选方法
HK1104836B (en) Recombinant alpha-l-iduronidase and methods for treating diseases caused by deficiencies thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE APPLICANT JOHN M HENSTRAND

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 09/439923 US 19991112

TC Change of applicant's name (sec. 104)

Owner name: BIOMARIN PHARMACEUTICAL INC., HARBOR-UCLA RESEARCH

Free format text: FORMER NAME: BIOMARIN PHARMACEUTICALS, HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND 1ST APPLICANT'S NAME TO READ: BIOMARIN PHARMACEUTICAL INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired